Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.

NCT05387603 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

300

Enrollment

OTHER

Sponsor class

Conditions

Neuroendocrine Tumors

Interventions

DRUG: 177Lu-DOTATOC
DRUG: Capecitabine

Sponsor

Lund University Hospital